Pfizer Global Regulatory Affairs Pfizer Inc. 400 Arcola Road Collegeville, PA 19426



Global Product Development

16 August 2021

Marion Gruber, Ph.D. Director Office of Vaccines Research and Review Food and Drug Administration Center for Biologics Evaluation and Research Document Control Center 10903 New Hampshire Avenue WO71, G112 Silver Spring, MD 20993-0002 THIS DOCUMENT CONTAINS CONFIDENTIAL AND/OR TRADE SECRET INFORMATION THAT IS DISCLOSED ONLY IN CONNECTION WITH THE LICENSING AND/OR REGISTRATION OF PRODUCTS FOR PFIZER INC OR ITS AFFILIATED COMPANIES. THIS DOCUMENT SHOULD NOT BE DISCLOSED OR USED, IN WHOLE OR IN PART, FOR ANY OTHER PURPOSE WITHOUT THE PRIOR WRITTEN CONSENT OF PFIZER INC.

Re: BLA 125742

COVID-19 mRNA Vaccine (BNT162/PF-07302048)

Response to FDA 13 August 2021 Information Requests

Dear Dr. Gruber,

Reference is made to the Biologics License Application (BLA) submitted 19 May 2021 for the COVID-19 mRNA Vaccine (BNT162/PF-07302048) developed by BioNTech and Pfizer under BB-IND 19736 for the prevention of COVID-19 caused by SARS-CoV-2 in individuals \geq 16 years of age.

The purpose of this submission is to respond to CBER's 13 August 2021 Information Requests, received via email from Captain Michael Smith, PhD (CBER). The requests are regarding duration of follow-up in Study C4591001 for subjects ≥ 16 years of age. Upon receiving the queries Pfizer/BioNTech requested additional clarification in relation to question 3 which was also provided on the same day by CBER. Subsequently, Pfizer/BioNTech received an additional question also related to the efficacy population. The Response to FDA 13 August 2021 Information Request is provided in Module 1.11.3.

Should you have any questions regarding this submission, or require additional information, please contact me via phone at 215-280-5503; via facsimile at 845-474-3500; or via e-mail at elisa.harkinstull@pfizer.com.

Sincerely,

Elisa Harkins Global Regulatory Lead Global Regulatory Affairs – Vaccines

CC: Ramachandra S. Naik, Ph.D.

Pfizer Confidential Page 2